诺沃·诺迪斯克(Novo Nordisk)以高达21亿美元的价格购买Omeros稀有疾病药物Zaltenibart的全球权利。 Novo Nordisk to buy global rights to Omeros’ rare disease drug zaltenibart for up to $2.1 billion.

诺沃·诺迪斯克同意获得Omeros实验药物Zaltenibart的专属全球权利,这是用于稀有血液和肾病的MASP-3抑制剂,价值高达21亿美元。 Novo Nordisk has agreed to acquire exclusive global rights to Omeros’ experimental drug zaltenibart, a MASP-3 inhibitor for rare blood and kidney disorders, in a deal worth up to $2.1 billion. 该协定包括一笔3.4亿美元的预付付款和潜在的里程碑付款。 The agreement includes a $340 million upfront payment and potential milestone payments. 在晚间性血红蛋白尿症的早期试验中,Zaltenibart已显示出安全性和耐受性,将在Novo的领导下进入全球第三阶段开发计划,并计划探索其他罕见疾病的应用. Zaltenibart, which has shown safety and tolerability in early trials for paroxysmal nocturnal hemoglobinuria, will enter a global phase 3 development program under Novo’s leadership, with plans to explore additional rare disease applications. 该交易预计将在2025年第四季度结束,在试验结果良好后进行,Omeros继续寻求对其其他药物Narsoplimab的监管批准。 The transaction, expected to close in the fourth quarter of 2025, follows positive trial results and Omeros’ continued pursuit of regulatory approval for its other drug, narsoplimab. Omeros保留了某些临床前期MASP-3方案的权利,在宣布后,其份额上升了100%以上。 Omeros retains rights to certain preclinical MASP-3 programs and saw its shares rise over 100% after the announcement.